Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten)....
BMY Positive Sentiment
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Key Takeaway: Bristol Myers Squibb presented new data at the ESC Congress 2026, showcasing the long-term efficacy and safety of Camzyos (mavacamten) in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The findings, which span up to five years, reinforce the drug's positive profile in managing this condition. This presentation underscores the importance of ongoing research in cardiovascular therapies.
Market Sentiment Analysis
POSITIVE FACTORS
- Long-term efficacy of Camzyos is reinforced by new data.
- Safety profile of Camzyos remains strong over five years.
- Presentation at a major congress highlights the drug's significance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+26%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Muraglitazar
Phase 2 · Dyslipidemia
Frequently Asked Questions
What is Camzyos used for?
Camzyos (mavacamten) is used to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
What new data was presented by BMY?
Bristol Myers Squibb presented data reinforcing the long-term efficacy and safety of Camzyos.
How long does the new data cover?
The new data presented covers up to five years of treatment with Camzyos.
Where was the data presented?
The data was presented at the European Society of Cardiology (ESC) Congress 2026.